Ultra-potent Antibodies Against Respiratory Syncytial Virus: Effects of Binding Kinetics and Binding Valence on Viral Neutralization
- 11 May 2005
- journal article
- Published by Elsevier in Journal of Molecular Biology
- Vol. 350 (1) , 126-144
- https://doi.org/10.1016/j.jmb.2005.04.049
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Surveillance of Clinical Isolates of Respiratory Syncytial Virus for Palivizumab (Synagis)–Resistant MutantsThe Journal of Infectious Diseases, 2004
- Quantitative Effects of Palivizumab and Donor-Derived T Cells on Chronic Respiratory Syncytial Virus Infection, Lung Disease, and Fusion Glycoprotein Amino Acid Sequences in a Patient Before and After Bone Marrow TransplantationClinical Infectious Diseases, 2004
- Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues 1 1Edited by J. A. WellsJournal of Molecular Biology, 1999
- A Direct Comparison of the Activities of Two Humanized Respiratory Syncytial Virus Monoclonal Antibodies: MEDI‐493 and RSHZl9The Journal of Infectious Diseases, 1999
- Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk InfantsPediatrics, 1998
- SWISS‐MODEL and the Swiss‐Pdb Viewer: An environment for comparative protein modelingElectrophoresis, 1997
- Isolation of Picomolar Affinity Anti-c-erbB-2 Single-chain Fv by Molecular Evolution of the Complementarity Determining Regions in the Center of the Antibody Binding SiteJournal of Molecular Biology, 1996
- Affinity Maturation of a High-affinity Human Monoclonal Antibody Against the Third Hypervariable Loop of Human Immunodeficiency Virus: Use of Phage Display to Improve Affinity and Broaden Strain ReactivityJournal of Molecular Biology, 1996
- CDR Walking Mutagenesis for the Affinity Maturation of a Potent Human Anti-HIV-1 Antibody into the Picomolar RangeJournal of Molecular Biology, 1995
- An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccinesVirus Research, 1994